- Four sales managers in key territories to initiate sales in
the US
- Senior Product Manager to coordinate US launch planned later
in the year
STOCKHOLM, Sept. 27, 2018 /PRNewswire/ -- IRRAS AB
(NASDAQ Stockholm: IRRAS) announced today that it has added key
talent to its commercial organization to drive sales of the
company's lead product, IRRAflow®, in the United States. Steve Crowell, John
Gessert, Anthony Maestas, and
Bryan Whalen have joined IRRAS as
Territory Managers. In addition, John
Unser has joined IRRAS as a Senior Product Manager to lead
the marketing efforts for IRRAflow. These individuals have
over 60 years of relevant commercial medical device experience and
have shown significant success in bringing innovative technologies
to market and building them toward standard of care.
After the addition of these first four Territory Managers, IRRAS
plans to continue the growth of its US salesforce in coming months
to meet growing interest for IRRAflow and establish national
clinical coverage.
"The United States is the
largest medical device market globally, and the recent FDA
clearance of IRRAflow offers a great opportunity to enter
this critically important market. The hiring of these experienced,
successful sales professionals will be a great asset for our
company as we finalize our plans to launch in the US," said
Will Martin, Chief Commercial
Officer of IRRAS.
"We are very excited about the possibilities for IRRAflow
in the US, and our ability to hire key sales professionals is of
paramount importance to our ability to capture market share," said
Kleanthis G. Xanthopoulos, Ph.D.,
President and CEO of IRRAS.
For more information, please contact:
Sweden
Fredrik Alpsten
CFO and Deputy CEO
+46-706-67-31-06
fredrik.alpsten@irras.com
USA
Kleanthis G. Xanthopoulos, Ph.D.
President & CEO
info@irras.com
About IRRAS
IRRAS AB (NASDAQ Stockholm: IRRAS) is a publicly-traded,
commercial-stage medical technology company focused on developing
and commercializing innovative solutions for brain surgery. The
Company's initial product, IRRAflow®, addresses the
complications associated with the current methods of managing
intracranial fluid by using a dual lumen catheter that combines
active irrigation with ongoing fluid drainage. IRRAflow
received FDA clearance in July
2018.
Regularly during treatment, the IRRAflow catheter is
automatically flushed to prevent common catheter occlusions from
forming. Because IRRAflow is a completely closed system, it
is designed to reduce the documented infection risk of
these procedures. Additionally, IRRAflow incorporates ICP
monitoring and uses a proprietary software to regulate treatment
based on desired pressure levels.
With its unique product portfolio, protected by property patents
and patent applications, IRRAS is well positioned to establish a
leadership position in the medical device market. IRRAS maintains
its headquarters in Stockholm,
Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier. Wildeco
is certified adviser of the Company.
The information was released for public disclosure, through the
agency of the contact person above, on September 27, 2018 at 8.00
a.m. (CET).
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/irras/r/irras-strengthens-us-commercial-organization-with-hiring-of-multiple-key-talents,c2629088
The following files are available for download:
http://mb.cision.com/Main/16550/2629088/916673.pdf
|
Press release
(PDF)
|